Stock Price Quote

NECTAR LIFESCIENCES LTD.

NSE : NECLIFEBSE : 532649ISIN CODE : INE023H01027Industry : Pharmaceuticals & DrugsHouse : Private
BSE33.25-0.11 (-0.33 %)
PREV CLOSE ( ) 33.36
OPEN PRICE ( ) 33.36
BID PRICE (QTY) 33.14 (5)
OFFER PRICE (QTY) 33.25 (199)
VOLUME 57192
TODAY'S LOW / HIGH ( )33.16 34.20
52 WK LOW / HIGH ( )18.71 45.7
NSE33.25-0.1 (-0.3 %)
PREV CLOSE( ) 33.35
OPEN PRICE ( ) 33.69
BID PRICE (QTY) 33.20 (1439)
OFFER PRICE (QTY) 33.25 (282)
VOLUME 320820
TODAY'S LOW / HIGH( ) 33.17 34.39
52 WK LOW / HIGH ( )18.65 45.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 27-06 1995
Management Info
Sanjiv Goyal - Chairman Sanjiv Goyal - Managing Director
Registered Office

Address Village Saidpura,Tehsil Dera Bassi, ,
Mohali Dist,
Punjab-147001

Phone 01762-308000 / 308001

Email cs@neclife.com

Website www.neclife.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX

NEWS

16May Nectar Lifesciences informs about news
Nectar Lifesciences has enclosed newspaper copy of Publication of Financ..
15Feb Nectar Lifesciences informs about news
Nectar Lifesciences has informed that it attached the copy of Newspaper..
28Dec Nectar Lifesciences informs about trad
Nectar Lifesciences has informed that the trading window of the Company..
05Aug Nectar Lifesciences submits board meet
Pursuant to Regulations 29, 30, 33 and other applicable Regulations of S..
10Feb Nectar Lifesciences informs about upda
Nectar Lifesciences has informed that the Nectar Lifesciences USA, LLC (..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit6.0000000000006150.0100000000023
Gross Profit 111.200000000001 182.750000000002
Operating Profit 499.8000000000011661.35
Net Sales 4413.7516856.32

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  948.05 (8.24%)
M.Cap ( in Cr)446.65
Shilpa Medicare (BSE)
peergroup  571.00 (8.21%)
M.Cap ( in Cr)5611.73
Neuland Laboratories (BSE)
peergroup  6528.65 (0.57%)
M.Cap ( in Cr)8410.63
Orchid Pharma (BSE)
peergroup  1190.95 (2.53%)
M.Cap ( in Cr)5954.42
Solara Active Pharma (BSE)
peergroup  447.30 (6.58%)
M.Cap ( in Cr)2144.82

Shareholding Pattern

PROMOTERS 55.8%
NON-INSTITUTION 27.21%
GOVERNMENT 0.02%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
FII 0%

About Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 33.25. Its current market capitalisation stands at Rs 750.15 Cr. In the latest quarter, company has reported Gross Sales of Rs. 17465.56 Cr and Total Income of Rs.15668.48 Cr. The company's management includes Neha Vaishnav, Puneet Sud, Indu Pal Kaur, Kuldip Kumar Bhasin, Rupinder Tewari, Meena Verma, Ajay Swaroop, Sanjiv Goyal, Sanjiv Goyal.

It is listed on the BSE with a BSE Code of 532649 , NSE with an NSE Symbol of NECLIFE and ISIN of INE023H01027. It's Registered office is at Village Saidpura,Tehsil Dera Bassi, Mohali Dist-147001, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashwani K Gupta & Associates, Datta Singla & Co, Deepak Jindal & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.